Header Logo

Connection

Gary Raskob to Aged, 80 and over

Back to Details
This is a "connection" page, showing publications Gary Raskob has written about Aged, 80 and over.
Gary Raskob
Connection Strength
0.696
Aged, 80 and over
  1. Incidence of Venous Thromboembolism in a Racially Diverse Population of Oklahoma County, Oklahoma. Thromb Haemost. 2021 Jun; 121(6):816-825.
    View in: PubMed
    Score: 0.129
  2. Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. J Thromb Haemost. 2014 Jun; 12(6):824-30.
    View in: PubMed
    Score: 0.081
  3. Exclusion of first-episode deep-vein thrombosis after-hours using D-dimer. Blood Coagul Fibrinolysis. 2007 Dec; 18(8):795-800.
    View in: PubMed
    Score: 0.052
  4. Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings. Chest. 2004 Mar; 125(3):851-5.
    View in: PubMed
    Score: 0.040
  5. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmacoeconomics. 2004; 22(9):605-20.
    View in: PubMed
    Score: 0.040
  6. Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021 12 02; 385(23):2161-2172.
    View in: PubMed
    Score: 0.034
  7. Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021 08 12; 385(7):609-617.
    View in: PubMed
    Score: 0.033
  8. Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis. Thromb Res. 2019 Dec; 184:58-61.
    View in: PubMed
    Score: 0.030
  9. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. Thromb Res. 2018 02; 162:7-14.
    View in: PubMed
    Score: 0.026
  10. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. Thromb Haemost. 2017 Oct; 117(10):1944-1951.
    View in: PubMed
    Score: 0.026
  11. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis. Thromb Haemost. 2017 10 05; 117(10):1944-1951.
    View in: PubMed
    Score: 0.025
  12. Aging and heparin-related bleeding. Arch Intern Med. 1996 Apr 22; 156(8):857-60.
    View in: PubMed
    Score: 0.023
  13. Cost effectiveness of diagnosis of deep vein thrombosis in symptomatic patients. Thromb Haemost. 1995 Jul; 74(1):189-96.
    View in: PubMed
    Score: 0.022
  14. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet. 2012 Jan 14; 379(9811):123-9.
    View in: PubMed
    Score: 0.017
  15. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23; 363(26):2487-98.
    View in: PubMed
    Score: 0.016
  16. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010 Dec; 104(6):1150-7.
    View in: PubMed
    Score: 0.016
  17. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 Aug 06; 361(6):594-604.
    View in: PubMed
    Score: 0.015
  18. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009 Apr; 101(4):762-9.
    View in: PubMed
    Score: 0.014
  19. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008 Sep 15; 112(6):2242-7.
    View in: PubMed
    Score: 0.014
  20. Predictive value of compression ultrasonography for deep vein thrombosis in symptomatic outpatients: clinical implications of the site of vein noncompressibility. Arch Intern Med. 2000 Feb 14; 160(3):309-13.
    View in: PubMed
    Score: 0.008
  21. Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. Arch Intern Med. 1998 Sep 28; 158(17):1909-12.
    View in: PubMed
    Score: 0.007
  22. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med. 1998 Jan 01; 128(1):1-7.
    View in: PubMed
    Score: 0.007
  23. The low-probability lung scan. A need for change in nomenclature. Arch Intern Med. 1995 Sep 25; 155(17):1845-51.
    View in: PubMed
    Score: 0.006
  24. Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol. 1994 Oct 01; 74(7):657-61.
    View in: PubMed
    Score: 0.005
  25. A noninvasive strategy for the treatment of patients with suspected pulmonary embolism. Arch Intern Med. 1994 Feb 14; 154(3):289-97.
    View in: PubMed
    Score: 0.005
  26. Clinical validity of a normal perfusion lung scan in patients with suspected pulmonary embolism. Chest. 1990 Jan; 97(1):23-6.
    View in: PubMed
    Score: 0.004
  27. Pulmonary embolism in outpatients with pleuritic chest pain. Arch Intern Med. 1988 Apr; 148(4):838-44.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.